The IMforte phase 3 trial is the first to show statistically significant improvements in both progression-free and overall survival with lurbinectedin plus atezolizumab as first-line maintenance in ES-SCLC.
Lurbinectedin plus atezolizumab nearly halved the risk of disease progression and reduced the risk of death by 27% compared to atezolizumab alone.
Hematologic adverse events were more frequent with the combination, with careful monitoring and supportive care necessary.
